Dr. Appel is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
6560 Fannin St
Ste 802
Houston, TX 77030Phone+1 713-441-3760Fax+1 713-793-7271
Education & Training
- University of Pennsylvania Health SystemResidency, Neurology, 1965 - 1966
- Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Neurology, 1961 - 1962
- Massachusetts General HospitalInternship, Internal Medicine, 1960 - 1961
- Columbia University Vagelos College of Physicians and SurgeonsClass of 1960
Certifications & Licensure
- TX State Medical License 1977 - 2025
- NC State Medical License 1967 - 1982
- American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- Investigator Alumnus Howard Hughes Medical Institute, 1976
- Elected Member The American Society for Clinical Investigation, 1969
- Super Doctor SuperDoctors.com
- Join now to see all
Clinical Trials
- Genomic Translation for Amyotrophic Lateral Sclerosis Care Start of enrollment: 2016 Jun 08
- T-regulatory Cells in ALS Start of enrollment: 2019 Aug 07
Publications & Presentations
PubMed
- 341 citationsImmune reactivity in a mouse model of familial ALS correlates with disease progressionMaria E. Alexianu, Milena Kozovska, Stanley H. Appel
Neurology. 2001-10-09 - 350 citationsCD4+ T cells support glial neuroprotection, slow disease progression, and modify glial morphology in an animal model of inherited ALSDavid R. Beers, Jenny S. Henkel, Weihua Zhao, Jinghong Wang, Stanley H. Appel
Proceedings of the National Academy of Sciences of the United States of America. 2008-10-07 - 443 citationsAn antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: A phase 1, randomised, first-in-man studyTimothy M. Miller, Alan Pestronk, William S. David, Jeffrey D. Rothstein, Ericka Simpson
The Lancet. Neurology. 2013-05-01
Press Mentions
- Energy Co. Makes $100,000 Donation to Houston HospitalSeptember 4th, 2024
- Coya Therapeutics Reports Data from Alzheimer’s Disease Therapy TrialApril 3rd, 2023
- Alzheimer’s Diagnoses Expected to Reach Nearly 13 Million by 2050, Says New ReportMarch 17th, 2023
- Join now to see all
Grant Support
- Clinical Trial: Phase I/II Trial Using Cyclophosphamide And Low-Dose IL-2 To InNational Center For Research Resources2011
- Using CD4+ T Cells As A Candidate Therapy To Slow Disease Progression In ALSNational Institute Of Neurological Disorders And Stroke2010–2011
- Clinical Trial: Phase I/II Trial Using Cyclophosphamide And Low-Dose IL-2 To INDNational Center For Research Resources2010
- The Role Of Microglia In Models Of ALSNational Institute Of Neurological Disorders And Stroke2005–2007
- The Role Of Microglia In Models Of ALSNational Institute Of Neurological Disorders And Stroke2004
- Selective Vulnerability Of Sporadic Neurodegenerative DiseaseNational Institute On Aging1997–2000
- Alzheimers Disease Research CenterNational Institute On Aging1994–2000
- ALS IGG Effects On Motorneuron UntrastructureFogarty International Center1996–1998
- Selective Neuronal Vulnerability In Sporadic ALSNational Institute Of Neurological Disorders And Stroke1994–1997
- Alzheimer'S Disease Research CenterNational Institute On Aging1989–1993
- NeurosciencesNational Institute Of Neurological Disorders And Stroke1988
- Neurosciences Training ProgramNational Institute Of Neurological Disorders And Stroke1985–1987
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: